BMS' Abilify Gains Third Pediatric Indication: Autism-Related Irritability
This article was originally published in The Pink Sheet Daily
New claim puts the atypical antipsychotic on par with J&J's Risperdal.
You may also be interested in...
US agency may face challenge of keeping May 4 meeting on patient-focused drug development focused on autism disease burden and current therapeutic approaches rather than vaccine safety.
Otsuka Holdings Co., the parent of Japanese drug maker Otsuka Pharmaceutical Co. Ltd., has scheduled its long-planned initial public offering for December 15
Still fueled by growth of the anti-psychotic Abilify, the Japanese pharma's parent company plans to list on the Tokyo Stock Exchange on December 15.